Dextrose solutions (2.5%, 5%)

Dextrose solutions represent an essential component of supportive care in small mammal medicine, providing both fluid volume and caloric support through the administration of glucose in various concentrations. Dextrose, also known as D-glucose, is a simple monosaccharide that serves as the primary energy source for cellular metabolism in mammals. In veterinary medicine, dextrose solutions are available in multiple concentrations including 2.5%, 5%, 10%, 25%, and 50%, with the lower concentrations most commonly used for general fluid therapy and the higher concentrations reserved for treating acute hypoglycemia or preparing diluted solutions. The mechanism of action is straightforward: dextrose provides readily available glucose that can be rapidly absorbed and utilized by cells for energy production through glycolysis and subsequent metabolic pathways.

The use of dextrose solutions in veterinary medicine has a long history paralleling their use in human medicine. These solutions became standard components of fluid therapy protocols as understanding of carbohydrate metabolism and fluid balance advanced throughout the twentieth century. In exotic small mammal practice, dextrose solutions gained particular importance with the recognition of conditions like insulinoma in ferrets, where maintaining adequate blood glucose levels is critical for patient survival. The development of small-volume delivery systems and micro-dosing techniques has made administration of these solutions safer and more practical in very small patients where precise volume control is essential.

Dextrose solutions are available in several forms suitable for different clinical applications in small mammals. Pre-mixed 5% dextrose in water (D5W) provides an isotonic solution suitable for intravenous administration. The 2.5% concentration, often prepared by diluting D5W with equal parts sterile water or other crystalloid solutions, offers a lower glucose load while still providing some caloric support. Higher concentrations such as 25% and 50% dextrose are hypertonic and must be used with extreme caution, typically diluted before administration or given only intravenously in emergency hypoglycemia situations. Dextrose can also be added to other crystalloid solutions like Lactated Ringer's or normal saline to create custom fluid combinations tailored to individual patient needs.

The general effectiveness and safety profile of appropriately concentrated dextrose solutions in small mammals is favorable when used correctly under veterinary supervision. Lower concentration solutions like 2.5% and 5% dextrose are well-tolerated by most species and provide modest caloric support alongside fluid volume. However, several important safety considerations apply: concentrated dextrose solutions are hypertonic and can cause tissue damage if administered subcutaneously or if extravasation occurs during intravenous administration. Rapid administration of glucose can trigger insulin release, potentially worsening hypoglycemia through rebound effects in some patients. Additionally, dextrose solutions do not contain electrolytes and are not appropriate as sole fluid therapy when electrolyte replacement is needed. Proper use requires veterinary guidance to select appropriate concentrations and administration routes for each clinical situation.

The primary uses of dextrose solutions in small mammals center on treating hypoglycemia and providing caloric support to debilitated patients. Acute hypoglycemia, characterized by dangerously low blood glucose levels, requires rapid glucose administration to prevent seizures, coma, and death. This condition can occur in various scenarios including prolonged anorexia, sepsis, liver disease, excessive insulin administration, and insulinoma. Dextrose solutions provide immediately available glucose that can restore blood sugar levels while the underlying cause is addressed. Beyond emergency treatment, lower concentration dextrose solutions serve as maintenance fluids that provide some caloric value during periods when patients cannot eat normally.

Species-specific applications of dextrose therapy vary based on the metabolic characteristics and common disease presentations of different small mammals. Ferrets represent a particularly important patient population for dextrose therapy due to the high prevalence of insulinoma, a pancreatic beta cell tumor that causes excessive insulin secretion and resultant hypoglycemia. Affected ferrets may require long-term management with frequent small meals and sometimes dextrose supplementation during hypoglycemic episodes. Hamsters and other small rodents with very high metabolic rates can develop hypoglycemia rapidly during illness or fasting and may benefit from dextrose supplementation. Neonatal small mammals of any species may need glucose support if they become separated from their mother or if the mother is not producing adequate milk.

Common conditions treated with dextrose solutions extend beyond primary hypoglycemia to include various situations where caloric and fluid support are beneficial. Post-operative patients recovering from anesthesia may benefit from dextrose-containing fluids, particularly if the procedure was lengthy or if pre-operative fasting was required. Animals with severe infections or sepsis often develop metabolic derangements including hypoglycemia and benefit from glucose supplementation. Hepatic disease can impair glycogen storage and gluconeogenesis, making affected animals dependent on exogenous glucose. Debilitated or anorexic patients may receive dextrose as part of partial parenteral nutrition support when enteral feeding is not possible or is insufficient.

Off-label and supportive care applications include using dextrose solutions as vehicles for medication delivery in some cases, though this is less common than using other crystalloid solutions for this purpose. Dextrose may be added to other fluid preparations to provide customized caloric support based on patient needs. In some emergency situations, concentrated dextrose can be applied to oral mucous membranes for rapid absorption in hypoglycemic patients who cannot receive intravenous access. Dilute dextrose solutions can also be used for oral supplementation in mildly hypoglycemic patients who are able to swallow safely.

Choosing dextrose solutions over alternatives depends on the specific clinical goals. When the primary need is caloric support alongside fluid therapy, dextrose-containing solutions offer advantages over plain crystalloids. However, when electrolyte replacement is the primary goal, balanced electrolyte solutions like Lactated Ringer's may be more appropriate either alone or with added dextrose. For severe hypoglycemia emergencies, concentrated dextrose provides the most rapid glucose delivery. The exotic veterinarian will determine the most appropriate fluid composition based on the patient's complete clinical picture, including hydration status, electrolyte values, blood glucose level, and underlying disease process.

General dosing principles for dextrose solutions in small mammals must be individualized based on the patient's species, body weight, clinical condition, and the specific indication for therapy. Specific numeric dosing recommendations should always come from the treating exotic veterinarian who can assess the individual patient and calculate appropriate volumes and concentrations. As a general concept, the goal is to provide adequate glucose to meet metabolic needs without causing hyperglycemia or fluid overload. Maintenance fluid requirements in small mammals are relatively high per unit body weight compared to larger animals due to higher metabolic rates, and any dextrose supplementation must be calculated within the context of total daily fluid needs.

Route of administration considerations significantly impact the safety and efficacy of dextrose therapy. Intravenous administration is the preferred route for hypoglycemia treatment because it provides immediate access to the bloodstream and allows for rapid correction of blood glucose levels. However, intravenous access can be challenging in very small patients and may not be practical in all clinical settings. Subcutaneous administration of dilute dextrose solutions (2.5% to 5%) is sometimes used for maintenance supplementation, though absorption is slower and less predictable than intravenous delivery. Importantly, concentrated dextrose solutions should never be given subcutaneously as they can cause significant tissue irritation and necrosis. Oral administration of dextrose or corn syrup can provide rapid mucosal absorption in conscious patients and is sometimes used for home management of mild hypoglycemic episodes.

Frequency and duration guidelines depend on the underlying condition being treated. Acute hypoglycemia requires immediate treatment followed by blood glucose monitoring to determine if additional doses are needed. Maintenance dextrose supplementation may be provided as a continuous intravenous infusion or incorporated into calculated fluid therapy given over hours to days. Ferrets with insulinoma may require ongoing management with frequent meals and rescue dextrose protocols for hypoglycemic episodes. The duration of supplementation depends on when the underlying cause is resolved or controlled. Blood glucose monitoring guides ongoing therapy, with adjustments made based on measured levels and clinical response.

Species-specific dosing considerations recognize that different small mammals have varying metabolic rates and susceptibility to glucose imbalances. Ferrets with insulinoma require careful glucose management that avoids both hypoglycemia and excessive glucose administration that could stimulate further insulin release. Very small species like hamsters and mice have extremely high metabolic rates and may become hypoglycemic quickly during illness but can also develop hyperglycemia if over-supplemented. Guinea pigs and chinchillas generally tolerate standard dextrose protocols well. The exotic veterinarian will consider species-specific factors when designing the treatment protocol.

Compounding and preparation requirements for dextrose solutions are generally minimal as pre-mixed solutions are commercially available. However, custom concentrations may be prepared by diluting higher concentration solutions with sterile water or other crystalloid fluids. When preparing diluted solutions, aseptic technique is essential to prevent contamination. Dextrose solutions do not contain preservatives and should be used promptly after preparation or stored according to facility protocols. Addition of dextrose to electrolyte solutions should be done carefully with attention to final concentration and compatibility.

Administration tips for veterinary staff and owners focus on safety and appropriate technique. Intravenous dextrose should be administered through properly placed and secured catheters with monitoring for extravasation. Flow rates should be controlled using appropriate delivery devices to prevent rapid bolus administration. For home management of ferrets with insulinoma, owners may be trained to administer corn syrup or honey to the gums during hypoglycemic episodes while transporting to the veterinarian. Owners should never attempt to give concentrated dextrose solutions at home without specific veterinary training and guidance. Blood glucose monitoring, when available, helps guide therapy and should be performed according to the veterinarian's instructions.

Common side effects of dextrose solution administration in small mammals are generally related to inappropriate concentration selection or administration technique rather than the glucose itself. Localized reactions at injection sites can occur, particularly with subcutaneous administration, and may include swelling, discomfort, or transient firmness at the injection site. These local reactions are more common and more severe with higher concentration solutions. Mild hyperglycemia may occur if glucose is provided in excess of metabolic needs, though small mammals with normal pancreatic function typically regulate blood glucose effectively through endogenous insulin release. Temporary changes in urination patterns may be noted as the kidneys handle the glucose load.

Gastrointestinal effects are minimal with parenteral dextrose administration since the glucose bypasses the digestive system entirely. However, if concentrated oral glucose preparations are used, some animals may experience mild digestive upset including soft stools or temporary appetite changes. The concern for dysbiosis that exists with oral antibiotics in small mammals is not applicable to glucose administration, as simple sugars do not directly disrupt the gut microbiome in the same manner as antimicrobial agents. That said, significant dietary changes including excessive simple sugar intake could theoretically affect gut bacterial populations over time, though this is rarely a concern with therapeutic dextrose use.

Species-specific adverse reactions to dextrose relate primarily to individual metabolic conditions rather than species-level sensitivities. Ferrets with insulinoma may experience a paradoxical response to glucose administration: while the immediate effect is to raise blood glucose, the increased glucose can stimulate additional insulin release from the tumor, potentially causing rebound hypoglycemia. This phenomenon requires careful management with small frequent feedings rather than large glucose boluses when possible. Diabetic or pre-diabetic small mammals, while uncommon, could experience significant hyperglycemia with glucose supplementation. Obese animals may have impaired glucose tolerance that affects their response to dextrose therapy.

Serious and rare side effects can occur with improper use of dextrose solutions. Extravasation of concentrated dextrose solutions (10% or higher) can cause significant tissue necrosis, particularly dangerous in small mammals with limited tissue mass for fluid absorption. Rapid intravenous administration of hypertonic dextrose can cause osmotic shifts with potential neurological consequences. Phlebitis may develop at intravenous catheter sites, especially with prolonged infusions or higher concentration solutions. Contamination of dextrose solutions can lead to sepsis, emphasizing the importance of aseptic technique and proper storage. Severe hyperglycemia, while uncommon with appropriate dosing, can cause osmotic diuresis, dehydration, and electrolyte imbalances.

Owners and veterinary staff should contact the supervising veterinarian if concerning signs develop during or after dextrose therapy. Signs warranting immediate attention include localized swelling, redness, or apparent pain at injection sites, which could indicate extravasation or tissue reaction. Neurological signs such as tremors, seizures, weakness, or altered mentation may indicate either persistent hypoglycemia or, less commonly, complications of therapy. Changes in urination pattern, excessive thirst, or signs of dehydration should be reported. In ferrets with insulinoma, any recurrence of hypoglycemic signs after initial treatment indicates the need for reassessment of the management protocol.

Species contraindications for dextrose solution use are relatively limited, as glucose is a fundamental metabolic substrate for all mammals. However, certain conditions make dextrose administration inappropriate or require significant caution. Known diabetic small mammals should not receive dextrose supplementation except under careful veterinary supervision with blood glucose monitoring, as they cannot appropriately regulate the glucose load. Animals with suspected or confirmed hyperglycemia from any cause should have blood glucose assessed before receiving dextrose. In cases of severe cerebral edema, hypertonic dextrose solutions may worsen brain swelling and should be avoided. Patients with anuric or severely oliguric renal failure may be unable to excrete excess glucose, leading to dangerous hyperglycemia.

Medical condition contraindications encompass several clinical scenarios requiring caution. Active hemorrhage may be worsened by hemodilution from any intravenous fluid administration, including dextrose solutions, and restoration of blood volume with appropriate products takes priority over glucose supplementation. Patients with known severe volume overload or congestive heart failure should not receive additional fluid volume without careful assessment of risks and benefits. Hyperkalemia may be temporarily worsened by dextrose administration in some cases as cellular uptake mechanisms are complex, though in other situations dextrose-insulin combinations are used therapeutically to lower potassium. Animals with severe hepatic failure may have impaired glucose metabolism that complicates dosing decisions.

Age, pregnancy, and nursing status considerations apply to dextrose therapy as they do to any medical intervention. Neonatal small mammals may actually be more likely to need glucose supplementation than adults due to limited glycogen stores and high metabolic demands, making dextrose an important supportive care tool in pediatric patients. Pregnant animals may have altered glucose metabolism and should be monitored appropriately. Nursing mothers with high metabolic demands from lactation may benefit from caloric support but should be monitored for appropriate response. Geriatric animals may have reduced metabolic reserves and altered glucose tolerance that affect dosing considerations. Individual assessment rather than categorical age-based restrictions guides appropriate use.

Situations when dextrose solutions should not be used include any scenario where the risks clearly outweigh benefits or where glucose administration could worsen the clinical condition. When electrolyte replacement is the primary therapeutic goal, using dextrose-containing solutions instead of balanced electrolyte solutions may fail to address the critical need. Concentrated dextrose should never be administered subcutaneously due to tissue toxicity risk. Dextrose solutions should not be given orally to obtunded or seizing patients due to aspiration risk. If hyperglycemia is already present, additional glucose is contraindicated until the underlying cause is determined and addressed. When fluid restriction is necessary, the caloric benefit of dextrose must be weighed against the volume of fluid required to deliver it.

Medications that may interact with dextrose solutions include several important categories relevant to small mammal medicine. Insulin and dextrose have an obvious interaction, with insulin driving cellular glucose uptake and potentially causing hypoglycemia if dextrose supplementation is discontinued without appropriate insulin adjustment. Corticosteroids such as prednisone and dexamethasone can elevate blood glucose levels through various mechanisms, potentially requiring adjustment of dextrose supplementation when these drugs are used concurrently. Some antibiotics are formulated with dextrose carriers, and the total glucose load should be considered when multiple dextrose-containing products are administered simultaneously. Diuretics may affect glucose handling and fluid balance in ways that influence dextrose therapy decisions.

Interactions affecting the efficacy of dextrose therapy primarily relate to medications or conditions that alter glucose metabolism. Medications that increase insulin release, such as certain sulfonylurea drugs occasionally used in veterinary medicine, may counteract the intended effect of glucose supplementation. Drugs that impair insulin release or action could lead to excessive hyperglycemia when combined with dextrose administration. Beta-adrenergic blocking agents may mask some signs of hypoglycemia and alter the metabolic response to glucose administration. Catecholamines and sympathomimetic drugs affect glucose metabolism and may influence blood glucose responses to dextrose therapy.

Interactions with supplements and dietary components are generally minimal with parenteral dextrose administration but deserve consideration. Concurrent oral feeding may provide additional glucose beyond what is accounted for in the dextrose therapy plan. Supplements containing chromium or other compounds marketed for glucose metabolism support could theoretically influence blood glucose responses. In ferrets with insulinoma, the timing of meals relative to any dextrose supplementation matters for overall glycemic control. Intravenous lipid emulsions, occasionally used for parenteral nutrition in small mammals, should be administered through separate lines or with attention to compatibility when combined with dextrose solutions.

Safe combinations and compatibility considerations are important for practical fluid therapy. Dextrose is commonly added to crystalloid solutions such as Lactated Ringer's solution and normal saline to provide combined electrolyte and caloric support. However, certain drugs are incompatible with dextrose solutions due to stability or solubility issues, and medications should not be added to dextrose solutions without confirming compatibility. Blood products should generally be administered through separate lines from dextrose-containing fluids. When multiple intravenous fluids and medications are needed, careful planning of administration routes and timing helps avoid incompatibility issues and ensures accurate dosing of all components.

Concentration-related warnings represent the most critical safety considerations for dextrose solution use in small mammals. Solutions containing greater than 5% dextrose are hypertonic and can cause significant tissue damage if administered by any route other than intravenous. Subcutaneous administration of concentrated dextrose solutions can cause necrosis, sloughing, and serious complications that may require extensive treatment or be life-threatening in small patients with limited tissue reserves. Even 5% dextrose is somewhat hypertonic and should be used with caution for subcutaneous administration. When concentrated dextrose must be used for severe hypoglycemia, it should only be given intravenously through a properly secured catheter with careful monitoring for extravasation.

Species-specific warnings address the unique vulnerabilities and metabolic characteristics of different small mammal groups. Ferrets with insulinoma require a nuanced approach to glucose management: while they need glucose to treat hypoglycemic episodes, excessive glucose can stimulate further insulin release and cause rebound hypoglycemia. The recommendation for these patients typically involves frequent small meals rather than large glucose boluses when possible. Very small species such as hamsters, gerbils, and mice present challenges due to their tiny body size, making precise volume measurement critical to avoid fluid overload or under-treatment. Animals with undiagnosed diabetes, though rare in most small mammal species, could experience dangerous hyperglycemia with glucose supplementation.

Monitoring requirements during dextrose therapy help ensure safe and effective treatment. Blood glucose measurement is the gold standard for guiding therapy, though practical limitations may prevent frequent monitoring in some settings. Clinical signs of hypoglycemia including weakness, tremors, seizures, and collapse should be monitored, with therapy adjusted based on response. Signs of hyperglycemia such as excessive urination, increased thirst, and lethargy should also be watched for, though these are less common complications. Injection sites should be monitored for signs of local reaction including swelling, redness, firmness, or apparent pain. Overall hydration status and cardiovascular parameters should be assessed, particularly in patients receiving significant fluid volumes.

Human safety considerations for handling dextrose solutions are minimal compared to many medications. These solutions are not toxic or hazardous through skin contact, though proper aseptic technique should be maintained to protect the patient from contamination. Needles and sharps used for administration should be disposed of properly. There are no zoonotic concerns related to dextrose administration, and no special protective equipment is required beyond standard practices for injectable medication handling.

Storage during treatment requires attention to solution stability and contamination prevention. Opened containers of dextrose solutions should be dated and used within the timeframe specified by facility protocols, typically within 24 hours for single-patient use. Solutions should be protected from extreme temperatures and examined for any particulate matter, cloudiness, or color changes before use. Multi-dose vials of concentrated dextrose should be handled with strict aseptic technique. Pre-mixed dextrose-crystalloid combinations prepared in advance should be labeled clearly with contents, date, and time of preparation.

Storage requirements for dextrose solutions follow standard guidelines for pharmaceutical-grade injectable fluids. Unopened containers should be stored at controlled room temperature, typically between 15 and 30 degrees Celsius, protected from excessive heat and freezing. Light exposure should be minimized, though dextrose itself is relatively stable to light degradation compared to some other pharmaceutical compounds. Storage areas should be clean and organized to allow easy identification of products and monitoring of expiration dates. Original packaging should be maintained until the product is ready for use, as packaging provides protection from contamination and physical damage.

Shelf life and stability considerations are important for maintaining product efficacy and safety. Commercially prepared dextrose solutions have expiration dates assigned by the manufacturer based on stability testing, and these dates should be respected. Once a container is opened, the contents should be used promptly or according to facility-specific protocols for multi-dose vials and bags. Dextrose solutions that have been prepared by diluting concentrated products have limited stability and should generally be used within 24 hours when stored under refrigeration or within several hours at room temperature. Any solution showing particulate matter, cloudiness, discoloration, or other abnormalities should be discarded regardless of expiration date.

Safe handling and disposal practices protect both patients and handlers while ensuring environmental responsibility. Aseptic technique should be used whenever accessing containers of dextrose solutions, including proper disinfection of access ports and use of sterile needles and syringes. Partially used containers should be handled according to facility infection control protocols, with single-patient use generally preferred for injectable solutions. Unused dextrose solutions can typically be disposed of through standard pharmaceutical waste streams or down drains following local regulations, as dextrose itself is not classified as hazardous waste. Sharps and other supplies used in administration should be disposed of in appropriate containers. Empty containers should be disposed of according to local recycling and waste management guidelines.

Hamsters, gerbils, mice, and rats have extremely high metabolic rates relative to their body size, making them susceptible to rapid development of hypoglycemia during illness, fasting, or stress. These tiny patients may benefit from dextrose supplementation during periods of anorexia or illness, but their small body size also means that precise dosing is critical to avoid complications from either under-treatment or volume overload. Intravenous access can be extremely challenging in these species, and dilute subcutaneous dextrose solutions or oral glucose supplementation may be more practical alternatives when severe hypoglycemia is not present. Blood glucose monitoring may require specialized equipment designed for small sample volumes. These species generally tolerate appropriate dextrose supplementation well when given at proper concentrations and volumes.

Guinea pigs and chinchillas have somewhat lower metabolic rates than smaller rodents but still require appropriate attention to glucose status during illness. These hindgut fermenters primarily derive energy from volatile fatty acid production through cecal fermentation, so their relationship to dietary and supplemental glucose differs somewhat from monogastric carnivores. However, they still require glucose for essential metabolic functions and can become hypoglycemic during severe illness. Guinea pigs have the additional consideration of requiring vitamin C supplementation, which can be provided concurrently with dextrose-containing fluids when appropriate. Chinchillas are sensitive to heat stress, and fluid therapy including dextrose supplementation should be conducted in a temperature-controlled environment to prevent hyperthermia.

Ferrets represent a species of particular importance for dextrose therapy discussions due to the high prevalence of insulinoma in this species. Middle-aged to older ferrets commonly develop these insulin-secreting pancreatic tumors, which cause recurrent hypoglycemic episodes that can be life-threatening. Management typically involves frequent small meals to maintain steady blood glucose levels, medical management with drugs like prednisone or diazoxide, and sometimes surgical intervention. During hypoglycemic crises, ferrets may need emergency glucose administration, but this should ideally be done with veterinary guidance as excessive glucose can stimulate further insulin release. Owners of ferrets with insulinoma are often trained in home management including application of corn syrup or honey to the gums during mild episodes. Unlike rodents, ferrets can safely receive beta-lactam antibiotics, and their carnivorous metabolism differs significantly from herbivorous small mammals.

Hedgehogs, sugar gliders, and other exotic small mammals each have metabolic characteristics that may influence their response to dextrose therapy. Hedgehogs have relatively low metabolic rates compared to rodents and may be less prone to rapid hypoglycemia, though they still require appropriate glucose management during illness. Sugar gliders have specialized dietary requirements and unique metabolic adaptations to their natural nectar-feeding diet, potentially affecting their glucose handling. These species, along with others such as degus, prairie dogs, and African pygmy dormice, should receive dextrose therapy based on individual assessment by an exotic veterinarian familiar with their specific metabolic needs. As always, consultation with an experienced exotic animal practitioner is essential for developing appropriate treatment protocols for these less commonly seen species.

Same-class alternatives and related glucose-containing products provide options for caloric and glycemic support in small mammals. Corn syrup and honey represent over-the-counter options that can be applied to oral mucous membranes for rapid absorption during hypoglycemic emergencies, making them practical tools for home first aid in animals prone to hypoglycemia such as ferrets with insulinoma. Concentrated glucose gels marketed for diabetic emergencies in humans can similarly be used in small mammals. Higher concentration dextrose solutions including 10%, 25%, and 50% dextrose are available for situations requiring more concentrated glucose delivery, though these hypertonic solutions require strict intravenous administration. Dextrose-containing combination fluids such as 5% dextrose in Lactated Ringer's solution or 5% dextrose in normal saline provide both glucose and electrolytes simultaneously.

Alternative parenteral fluid options that do not contain glucose serve different therapeutic goals. Lactated Ringer's solution provides balanced electrolyte replacement without glucose, appropriate when hydration and electrolyte correction are the primary needs without concern for hypoglycemia. Normal saline (0.9% sodium chloride) offers sodium and chloride replacement in a simple crystalloid solution. Normosol-R and Plasma-Lyte represent other balanced electrolyte solutions with slightly different compositions. These non-glucose-containing fluids may be preferred when hyperglycemia is a concern or when the patient's caloric needs can be met through enteral feeding. The choice between dextrose-containing and non-dextrose fluids depends on the patient's complete clinical picture as assessed by the veterinarian.

Combination therapy approaches often integrate dextrose solutions with other supportive care measures. Dextrose may be added to balanced electrolyte solutions to create customized fluids meeting both hydration and caloric needs. For ferrets with insulinoma, dextrose therapy is typically combined with frequent feeding schedules and medical management with drugs such as prednisone to reduce insulin effects or diazoxide to suppress insulin release. In critically ill patients, dextrose-containing fluids may be part of a comprehensive supportive care protocol including temperature management, pain control, and treatment of underlying disease. B vitamins, particularly thiamine, may be supplemented alongside dextrose therapy in malnourished patients to prevent complications of glucose metabolism without adequate vitamin cofactors.